NCT02568878PHASE3Recruiting
Creatine for Depressed Male and Female Methamphetamine Users
Montana State University
Start Date
11/1/2015
Completion Date
5/1/2017
Summary
* Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression
Eligibility Criteria
Age Range: 18 years to 59 years
Inclusion Criteria:
* Current primary diagnosis of methamphetamine dependence or abuse, with methamphetamine preferred drug of abuse
* Current diagnosis of major depressive disorder (primary or substance-induced)
* Current diagnosis of an anxiety disorder (primary or substance-induced)
* Current Hamilton Depression Rating scale score \> or = to 16
* Current Hamilton Anxiety Scale score \> = to 18
* If taking a psychotropic medication for depressed or anxious mood, regimen must be stable for \> = to 4 weeks prior to creatine treatment initiation
Exclusion Criteria:
* Persons unable to provide adequate informed consent
* Persons who are at clinically significant suicidal or homicidal risk
* Primary substance-related diagnosis other than methamphetamine dependence or abuse
* Positive pregnancy test (females only)
* History of renal disease
* Clinically significant medical or neurological illness identified by history, physical exam and laboratory testing
* History of hypersensitivity reaction to creatine
Interventions
DRUG
Creatine monohydrate
Conditions
DepressionAnxietyMethamphetamine Dependence
Locations
Montana State University College of Nursing (Missoula campus)
Missoula, Montana 59812
United States